Close Menu

NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet a requirement to remain listed on the Nasdaq Capital Market, the company said in a document filed last week with the US Securities and Exchange Commission.

In a November 20 letter from Nasdaq, BG Medicine was told that it did not meet the minimum $2.5 million in stockholders' equity required for listing on the exchange, putting the company at risk of being delisted. For the period ended Sept. 30, 2014, BG Medicine reported stockholders' equity of $1.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.